These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 16957966)

  • 1. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era.
    Bonvalot S; Eldweny H; Péchoux CL; Vanel D; Terrier P; Cavalcanti A; Robert C; Lassau N; Cesne AL
    Ann Surg Oncol; 2006 Dec; 13(12):1596-603. PubMed ID: 16957966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.
    Andtbacka RH; Ng CS; Scaife CL; Cormier JN; Hunt KK; Pisters PW; Pollock RE; Benjamin RS; Burgess MA; Chen LL; Trent J; Patel SR; Raymond K; Feig BW
    Ann Surg Oncol; 2007 Jan; 14(1):14-24. PubMed ID: 17072676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
    Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors.
    Kobayashi K; Szklaruk J; Trent JC; Ensor J; Ahrar K; Wallace MJ; Madoff DC; Murthy R; Hicks ME; Gupta S
    Am J Clin Oncol; 2009 Dec; 32(6):574-81. PubMed ID: 19636238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor].
    Shen L; Jin ML
    Zhonghua Zhong Liu Za Zhi; 2004 Nov; 26(11):697-9. PubMed ID: 15777512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response.
    Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Sohn HJ; Lee JS; Kang YK
    Jpn J Clin Oncol; 2006 Nov; 36(11):704-11. PubMed ID: 17068083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
    Rutkowski P; Debiec-Rychter M; Nowecki ZI; Wozniak A; Michej W; Limon J; Siedlecki JA; Jerzak Vel Dobosz A; Grzesiakowska U; Nasierowska-Guttmejer A; Sygut J; Nyckowski P; Krawczyk M; Ruka W
    Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST).
    Fiore M; Palassini E; Fumagalli E; Pilotti S; Tamborini E; Stacchiotti S; Pennacchioli E; Casali PG; Gronchi A
    Eur J Surg Oncol; 2009 Jul; 35(7):739-45. PubMed ID: 19110398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].
    Wan DS; Wu XJ; Pan ZZ; Zhou ZW; Chen G; Li LR; Lu ZH; Ding PR
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(43):3064-7. PubMed ID: 17288838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).
    Sym SJ; Ryu MH; Lee JL; Chang HM; Kim TW; Kim HC; Kim KH; Yook JH; Kim BS; Kang YK
    J Surg Oncol; 2008 Jul; 98(1):27-33. PubMed ID: 18452195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
    Blanke CD; Rankin C; Demetri GD; Ryan CW; von Mehren M; Benjamin RS; Raymond AK; Bramwell VH; Baker LH; Maki RG; Tanaka M; Hecht JR; Heinrich MC; Fletcher CD; Crowley JJ; Borden EC
    J Clin Oncol; 2008 Feb; 26(4):626-32. PubMed ID: 18235122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of imatinib (STI571) on metastatic gastrointestinal stromal tumors: report of a case.
    Ando Y; Tsunoda T; Beck Y; Takayama T; Tahara H
    Surg Today; 2005; 35(2):157-60. PubMed ID: 15674500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    McAuliffe JC; Lazar AJ; Yang D; Steinert DM; Qiao W; Thall PF; Raymond AK; Benjamin RS; Trent JC
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6727-34. PubMed ID: 18006774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib mesylate treatment for advanced gastrointestinal stromal tumor: a pilot study focusing on patients experiencing sole liver metastasis after a prior radical resection.
    Zhu J; Wang Y; Hou M; Li HY; Zhang J
    Oncology; 2007; 73(5-6):324-7. PubMed ID: 18497504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Surgical treatment for patients with advanced gastrointestinal stromal tumor after targeted therapy].
    Wang CM; Shi YQ; Ye YW; Fu H; Zhao GF; Zhou Y; DU CY; Dong RZ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Mar; 12(2):155-8. PubMed ID: 19296251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
    Miyake M; Takeda Y; Hasuike Y; Kashiwazaki M; Mishima H; Ikenaga M; Mano M; Takada Y; Hirota S; Tsujinaka T
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate.
    Rutkowski P; Nowecki Z; Nyckowski P; Dziewirski W; Grzesiakowska U; Nasierowska-Guttmejer A; Krawczyk M; Ruka W
    J Surg Oncol; 2006 Mar; 93(4):304-11. PubMed ID: 16496358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.
    Blay JY; Le Cesne A; Ray-Coquard I; Bui B; Duffaud F; Delbaldo C; Adenis A; Viens P; Rios M; Bompas E; Cupissol D; Guillemet C; Kerbrat P; Fayette J; Chabaud S; Berthaud P; Perol D
    J Clin Oncol; 2007 Mar; 25(9):1107-13. PubMed ID: 17369574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate.
    Steinert DM; Oyarzo M; Wang X; Choi H; Thall PF; Medeiros LJ; Raymond AK; Benjamin RS; Zhang W; Trent JC
    Cancer; 2006 Apr; 106(7):1617-23. PubMed ID: 16518826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib mesylate therapy in advanced gastrointestinal stromal tumors: experience from a single institute.
    Hsiao HH; Liu YC; Tsai HJ; Chen LT; Lee CP; Chuan CH; Wang JY; Yang SF; Tseng YT; Lin SF
    Kaohsiung J Med Sci; 2006 Dec; 22(12):599-603. PubMed ID: 17116620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.